Hertzel C. Gerstein

Hertzel C. Gerstein

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Hertzel C. Gerstein

Population Health Research Institute, McMaster University, Hamilton, ON, Canada

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in The Lancet
Verified
Journal Article
Closed access
HGHertzel C Gerstein
Hertzel C Gerstein
HCHelen M Colhoun
Helen M Colhoun
GDGilles R Dagenais
Gilles R Dagenais
RDRafael Diaz
Rafael Diaz
MLMark Lakshmanan
Mark Lakshmanan
WZWilliam Zigrang
William Zigrang

25 July 2001 in JAMA
Verified
Journal Article
Closed access
PDF file
HGHertzel C. Gerstein
Hertzel C. Gerstein
JMJohannes F. E. Mann
Johannes F. E. Mann
QYQilong Yi
Qilong Yi
BZBernard Zinman
Bernard Zinman
SDSean F. Dinneen
Sean F. Dinneen
SYSalim Yusuf
Salim Yusuf
Research from JAMA — Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals — ContextMicroalbuminuria is a risk factor for cardiovascular (CV) events. The relationship between the degree of albuminuria and CV risk is unclear.ObjectivesTo estimate the risk of CV events in high-risk individuals with diabetes mellitus (DM) and without DM who have microalbuminuria and to determine whether levels of albuminuria below the microalbuminuria threshold increase CV risk.DesignThe Heart Outcomes Prevention Evaluation study, a cohort study conducted between 1994 and 1999 with a median 4.5 years of follow-up.SettingCommunity and academic practices in North and South America and Europe.ParticipantsIndividuals aged 55 years or more with a history of CV disease (n = 5545) or DM and at least 1 CV risk factor (n = 3498) and a baseline urine albumin/creatinine ratio (ACR) measurement.Main Outcome MeasuresCardiovascular events (myocardial infarction, stroke, or CV death); all-cause death; and hospitalization for congestive heart failure.ResultsMicroalbuminuria was detected in 1140 (32.6%) of those with DM and 823 (14.8%) of those without DM at baseline. Microalbuminuria increased the adjusted relative risk (RR) of major CV events (RR, 1.83; 95% confidence interval [CI], 1.64-2.05), all-cause death (RR, 2.09; 95% CI, 1.84-2.38), and hospitalization for congestive heart failure (RR, 3.23; 95% CI, 2.54-4.10). Similar RRs were seen for participants with or without DM, even after adjusting for other CV risk factors (eg, the adjusted RR of the primary aggregate end point was 1.97 [95% CI, 1.68-2.31] in those with DM and 1.61 [95% CI, 1.36-1.90] in those without DM).Compared with the lowest quartile of ACR (1.62 mg/mmol) (P for trend <.001, even after excluding those with microalbuminuria). For every 0.4-mg/mmol increase in ACR level, the adjusted hazard of major CV events increased by 5.9% (95% CI, 4.9%-7.0%).ConclusionsOur results indicate that any degree of albuminuria is a risk factor for CV events in individuals with or without DM; the risk increases with the ACR, starting well below the microalbuminuria cutoff. Screening for albuminuria identifies people at high risk for CV events.

1 March 2000 in The Lancet
Verified
Journal Article
Closed access
SCSarah E Capes
Sarah E Capes
DHDereck Hunt
Dereck Hunt
KMKlas Malmberg
Klas Malmberg
HGHertzel C Gerstein
Hertzel C Gerstein

1 October 2001 in Stroke
Verified
Journal Article
Closed access
SCSarah E. Capes
Sarah E. Capes
DHDereck Hunt
Dereck Hunt
KMKlas Malmberg
Klas Malmberg
PPParbeen Pathak
Parbeen Pathak
HGHertzel C. Gerstein
Hertzel C. Gerstein
Background and Purpose “Stress” hyperglycemia may be associated with increased mortality and poor recovery in diabetic and nondiabetic patients after stroke. A systematic review and meta-analysis of the literature relating acute poststroke glucose levels to the subsequent course were done to summarize and quantify this relationship. Methods A comprehensive literature search was done for cohort studies reporting mortality and/or functional recovery after stroke in relation to admission glucose level. Relative risks in hyperglycemic compared with normoglycemic patients with and without diabetes were calculated and meta-analyzed when possible. Results Thirty-two studies were identified; relative risks for prespecified outcomes were reported or could be calculated in 26 studies. After stroke of either subtype (ischemic or hemorrhagic), the unadjusted relative risk of in-hospital or 30-day mortality associated with admission glucose level >6 to 8 mmol/L (108 to 144 mg/dL) was 3.07 (95% CI, 2.50 to 3.79) in nondiabetic patients and 1.30 (95% CI, 0.49 to 3.43) in diabetic patients. After ischemic stroke, admission glucose level >6.1 to 7.0 mmol/L (110 to 126 mg/dL) was associated with increased risk of in-hospital or 30-day mortality in nondiabetic patients only (relative risk=3.28; 95% CI, 2.32 to 4.64). After hemorrhagic stroke, admission hyperglycemia was not associated with higher mortality in either diabetic or nondiabetic patients. Nondiabetic stroke survivors whose admission glucose level was >6.7 to 8 mmol/L (121 to 144 mg/dL) also had a greater risk of poor functional recovery (relative risk=1.41; 95% CI, 1.16 to 1.73). Conclusions Acute hyperglycemia predicts increased risk of in-hospital mortality after ischemic stroke in nondiabetic patients and increased risk of poor functional recovery in nondiabetic stroke survivors.

1 February 1999 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
MCM Coutinho
M Coutinho
HGH C Gerstein
H C Gerstein
YWY Wang
Y Wang
SYS Yusuf
S Yusuf
OBJECTIVE: To assess the relationship between nondiabetic glucose levels and cardio vascular risk. RESEARCH DESIGN AND METHODS: Three independent searches using MEDLINE (1966-1996), followed by a manual search of the references from each retrieved article, were conducted by two physicians and one medical librarian. Data had to be reported in at least three quantiles or intervals so that the nature of the relationship between glucose and cardiovascular events (i.e., linear or nonlinear) could be explored, and to ensure that any incremental cardiovascular risk was consistent across quantiles or intervals. RESULTS: Analyzed studies comprised 95,783 people (94% male) who had 3,707 cardiovascular events over 12.4 years (1,193,231 person-years). Studies reporting fasting glucose levels (n = 6), 2-h glucose levels (n = 7), 1-h glucose levels (n = 5), and casual glucose levels (n = 4) were included. The glucose load used varied from 50 to 100 g. The highest glucose interval for most studies included glucose values in the diabetic range. The relationship between glucose levels and the risk of a cardiovascular event was modeled for each study and the beta-coefficients were combined. Compared with a glucose level of 4.2 mmol/l (75 mg/dl), a fasting and 2-h glucose level of 6.1 mmol/dl (110 mg/dl) and 7.8 mmol/l (140 mg/dl) was associated with a relative cardiovascular event risk of 1.33 (95% CI 1.06-1.67) and 1.58 (95% CI 1.19-2.10), respectively. CONCLUSIONS: The progressive relationship between glucose levels and cardiovascular risk extends below the diabetic threshold.

1 September 2006 in The Lancet
Verified
Journal Article
Closed access
DIDREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
HGH C Gerstein
H C Gerstein
SYS Yusuf
S Yusuf
JBJ Bosch
J Bosch
JPJ Pogue
J Pogue
RHR R Holman
R R Holman